ArticleAmerican journal of clinical dermatology2025

A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis.

Linda Stein Gold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.